ENANTA PHARMACEUTICALS INC
ENTA · XNASCIK 1177648fmd_1A65DBRVD7WJK1W9R05GRE5DS0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2010 to Jun 30, 2026, 60 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 88 | 103 | 207 | 205 | 122 | 97 | 86 | 79 | 68 | 65 |
| Research and development | 40 | 57 | 95 | 142 | 137 | 174 | 165 | 164 | 131 | 107 |
| Operating income | 31 | 25 | 88 | 37 | (42) | (110) | (124) | (137) | (122) | (85) |
| Interest expense | 0 | 0 | – | – | – | 0 | 0 | 5 | 11 | 8 |
| Interest and investment income | 2 | 3 | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 2 | 2 | 5 | 9 | 7 | 2 | 2 | 6 | 4 | 2 |
| Income before taxes | 33 | 27 | 93 | 46 | (35) | (108) | (122) | (131) | (118) | (84) |
| Income tax expense | 11 | 9 | 21 | (1) | 1 | (29) | (0) | 3 | (2) | (2) |
| Net income from continuing operations | 22 | 18 | 72 | 46 | (36) | (79) | (122) | (134) | (116) | (82) |
| Net income | 22 | 18 | 72 | 46 | (36) | (79) | (122) | (134) | (116) | (82) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |